The stock of Lyell Immunopharma Inc (NASDAQ: LYEL) has increased by 14.98 when compared to last closing price of 2.19. Despite this, the company has experienced a 21.06% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-07 that Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let’s find out.
Is It Worth Investing in Lyell Immunopharma Inc (NASDAQ: LYEL) Right Now?
The 36-month beta value for LYEL is at -0.56. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LYEL is 116.53M, and currently, shorts hold a 8.90% of that float. The average trading volume for LYEL on April 09, 2024 was 924.46K shares.
LYEL’s Market Performance
LYEL’s stock has seen a 21.06% increase for the week, with a 0.32% rise in the past month and a 18.77% gain in the past quarter. The volatility ratio for the week is 6.13%, and the volatility levels for the past 30 days are at 8.02% for Lyell Immunopharma Inc The simple moving average for the last 20 days is 19.58% for LYEL stock, with a simple moving average of 17.46% for the last 200 days.
Analysts’ Opinion of LYEL
Many brokerage firms have already submitted their reports for LYEL stocks, with JP Morgan repeating the rating for LYEL by listing it as a “Neutral.” The predicted price for LYEL in the upcoming period, according to JP Morgan is $5 based on the research report published on August 28, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see LYEL reach a price target of $7, previously predicting the price at $15. The rating they have provided for LYEL stocks is “Equal-Weight” according to the report published on November 14th, 2022.
Goldman gave a rating of “Neutral” to LYEL, setting the target price at $7 in the report published on November 11th of the previous year.
LYEL Trading at 16.42% from the 50-Day Moving Average
After a stumble in the market that brought LYEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.57% of loss for the given period.
Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 6.13%, as shares surge +5.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.51% upper at present.
During the last 5 trading sessions, LYEL rose by +18.51%, which changed the moving average for the period of 200-days by -25.08% in comparison to the 20-day moving average, which settled at $2.11. In addition, Lyell Immunopharma Inc saw 29.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYEL starting from Klausner Richard, who sale 58,020 shares at the price of $2.28 back on Aug 15 ’23. After this action, Klausner Richard now owns 930,880 shares of Lyell Immunopharma Inc, valued at $132,286 using the latest closing price.
Stock Fundamentals for LYEL
Current profitability levels for the company are sitting at:
- -1902.54 for the present operating margin
- -150.75 for the gross margin
The net margin for Lyell Immunopharma Inc stands at -2310.02. The total capital return value is set at -0.35. Equity return is now at value -31.53, with -27.81 for asset returns.
Based on Lyell Immunopharma Inc (LYEL), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -2.59. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -3.77.
Currently, EBITDA for the company is -213.84 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 4300.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.07.
Conclusion
In conclusion, Lyell Immunopharma Inc (LYEL) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
